Prospects for pharmacological adaptation of neurovascular unit in conditions of neurotropic viral infection

Putilina M.V.; Teplova N.V.; Poryadin G.V.

doi:https://doi.org/10.17116/jnevro2021121051144

Close metadata

Recommended articles:

The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48

The role of drug Cytoflavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146

A comparative assessment of neurochemical and neurophysiological parameters of cardiac surgery patients who underwent different versions of multitasking cognitive training. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):62-68

Neurometabolic therapy with Cerebrolysin in patients with sepsis-associated encephalopathy. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):46-54

Localization features of FAP-positive activated stromal cells in fibrosis in patients with new coronavirus infection COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14

Laparoscopic appendectomy for appendiceal mucocele in a patient with COVID-19. Endoscopic Surgery. 2024;(6):41-45

Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medicine. 2024;(12):114-121

Selective anosmia for monomolecular odorants in a cohort of young individuals. Russian Rhinology. 2024;(4):262-268

The results of the examination of patients with chronic generalized periodontitis after novel coronavirus infection. Russian Journal of Stomatology. 2024;(4):18-22

Waiting for Disease X: a plan for preparing Russian laboratory services for the next pandemic. Laboratory Service. 2024;(4):5-11

Abstract:

The article discusses the prospects for pharmacological conditioning as a method for adaptation of neurovascular unit in conditions of neurotropic viral infection. A step-by-step mechanism for development of preconditioning and postconditioning is presented with a detailed description of it’s main stages (trigger, signal and effector). The role of neuroinflammation as the leading mechanism of damage and the possibility of influencing the brain neurotrophic factor are considered. It is shown that different medications including neurotrophic drugs (cerebrolysin) can serve as inducers of conditioning. Usage of neurotrophic drugs in different doses for preconditioning and postconditioning is pathogenetically justified.

Keywords:

neurotropic viruses

SARS-CoV-2

COVID-19

pharmacological adaptation

pharmacological conditioning

preconditioning

postconditioning

neurovascular unit

neuroinflammation

brain neurotrophic factor

neurotrophic drugs

cerebrolysin

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Teplova N.V.

Pirogov Russian National Research Medical University

SPIN RSCI: 9056-1948
Scopus AuthorID: 6603037947
ORCID: 0000-0003-4259-0945

Poryadin G.V.

Pirogov Russian National Research Medical University

Received:

02.03.2021

Accepted:

06.04.2021

Close metadata

References:

Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol. 2020;70(9):311‐322. https://doi.org/10.33588/rn.7009.2020179
Van den Pol AN. Viral infection leading to brain dysfunction: more prevalent than appreciated? Neuron. 2009;64(1):17-20. https://doi.org/10.1016/j.neuron.2009.09.023
Putilina MV, Grishin DV. SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):58-64. (In Russ.). https://doi.org/10.17116/jnevro202012008258
Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014;8:315. https://doi.org/10.3389/fnins.2014.00315
Wongchitrat P, Shukla M, Sharma R, Govitrapong P, Reiter RJ. Role of Melatonin on Virus-Induced Neuropathogenesis-A Concomitant Therapeutic Strategy to Understand SARS-CoV-2 Infection. Antioxidants (Basel). 2021;10(1):47. https://doi.org/10.3390/antiox10010047
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020;77(8):1018-1027. https://doi.org/10.1001/jamaneurol.2020.2065
Ludewig P, Winneberger J, Magnus T. The cerebral endothelial cell as a key regulator of inflammatory processes in sterile inflammation. J Neuroimmunol. 2019;326:38-44. https://doi.org/10.1016/j.jneuroim.2018.10.012
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2). https://doi.org/10.23812/CONTI-E
Gülke E, Gelderblom M, Magnus T. Danger signals in stroke and their role on microglia activation after ischemia. Ther Adv Neurol Disord. 2018; 11:1756286418774254. https://doi.org/10.1177/1756286418774254
Liang SY. Sepsis and Other Infectious Disease Emergencies in the Elderly. Emerg Med Clin North Am. 2016;34(3):501-522. https://doi.org/10.1016/j.emc.2016.04.005
Putilina MV. The role of arterial hypertension in the development of chronic cerebrovascular accident. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(9):124-128.
Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2020;267(8):2179-2184. Epub 2020 May 26. PMID: 32458193; PMCID: PMC7249973. https://doi.org/10.1007/s00415-020-09929-7
Lambert NJ, Survivor Corps. COVID-19 ‘Long Hauler’ Symptoms Survey Report. Indiana University School of Medicine. 2020. Accessed March 18, 2021. https://www.survivorcorps.com/reports
Levchenkova OS, Novikov VE. Possibilities of Pharmacological Preconditioning. Annals of the Russian Academy of Medical Sciences. 2016;71(1):16-24. https://doi.org/10.15690/vramn626
Deryagin OG, Gavrilova SA, Gainutdinov KL, Golubeva AV, Andrianov VV, Yafarova GG, Buravkov SV and Koshelev VB. Molecular Bases of Brain Preconditioning. Front Neurosci. 2017;11:427. https://doi.org/10.3389/fnins.2017.00427
Yakovlev AA, Lyzhin AA, Aleksandrova OP, Khaspekov LG, Gulyaeva NV. Trophic factors deprivation induces long-term protection of neurons against excitotoxic damage. Biomeditsinskaya khimiya. 2016;62(6):656-663. (In Russ.). https://doi.org/10.18097/PBMC20166206656
Spindler KR, Hsu TH. Viral disruption of the blood-brain barrier. Trends Microbiol. 2012;20(6):282-290. https://doi.org/10.1016/j.tim.2012.03.009
Putilina MV. Neuroprotective therapy of chronic cerebral ischemia. Vrach. 2008;8:27-32. (In Russ.).
Zarubina IV, Shabanov PD. Ot idei S.P. Botkina o «predvozdejstvii» do fenomena prekonditsionirovaniya. Perspektivy primeneniya fenomenov ishemicheskogo i farmakologicheskogo prekonditsionirovaniya. Revievs in Clinical Pharmacology and Drug Therapy. 2016;14:1:4-28. (In Russ.).
Mao J, Lin E, He L, Yu J, Tan P, Zhou Y. Autophagy and Viral Infection. In: Cui J, ed. Autophagy Regulation of Innate Immunity. Advances in Experimental Medicine and Biology. Springer, Singapore. 2019;1209:55-78. https://doi.org/10.1007/978-981-15-0606-2_5
Paul P, Münz C. Autophagy and Mammalian Viruses: Roles in Immune Response, Viral Replication, and Beyond. Adv Virus Res. 2016;95:149-195. https://doi.org/10.1016/bs.aivir.2016.02.002
Yang Y, Klionsky DJ. Autophagy and disease: unanswered questions. Cell Death Differ. 2020;27(3):858-871. https://doi.org/10.1038/s41418-019-0480-9
Frank MG, Weber MD, Watkins LR, Maier SF. Stress sounds the alarmin: The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. Brain Behav Immun. 2015;48:1-7. https://doi.org/10.1016/j.bbi.2015.03.010
Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, de Vries EFJ. Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2019;56(5):3295-3312. https://doi.org/10.1007/s12035-018-1283-6
Ahmad L, Mostowy S, Sancho-Shimizu V. Autophagy-Virus Interplay: From Cell Biology to Human Disease. Front. Cell Dev. Biol. 20186:155. https://doi.org/10.3389/fcell.2018.00155
Bernstein DL, Zuluaga-Ramirez V, Gajghate S. miR-98 reduces endothelial dysfunction by protecting blood-brain barrier (BBB) and improves neurological outcomes in mouse ischemia/reperfusion stroke model. Journal of Cerebral Blood Flow & Metabolism. 2020;40(10):1953-1965. https://doi.org/10.1177/0271678X19882264
Ludewig P, Winneberger J, Magnus T. The cerebral endothelial cell as a key regulator of inflammatory processes in sterile inflammation. J Neuroimmunol. 2019;326:38-44. https://doi.org/10.1016/j.jneuroim.2018.10.012
Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature. Int J Stroke. 2020;15(4):385-389. https://doi.org/10.1177/1747493020921664
Belokrylov GA, Molchanov IV. Levamin and cerebrolysin as immunostimulants. Byulleten’ eksperimental’noj biologii i meditsiny. 1991;2:165-166. PMID: 1611065. (In Russ.). https://doi.org/10.18097/PBMC20166206656
Georgy GS, Nassar NN, Mansour HA, Abdallah DM. Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats. PLoS One. 2013;8(6):e64847. https://doi.org/10.1371/journal.pone.0064847
Bekker RA, Bykov YuV. Cerebrolysin in psychiatric practice: mechanisms of action and therapeutic efficacy. Psychiatry and Psychopharmacotherapy. 2020;3:32-48.
Rockenstein E, Ubhi K, Trejo M. Cerebrolysin efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. BMC Neuroscience. 2014;90. https://doi.org/10.1186/1471-2202-15-90
Schauer E, Wronski R, Patockova J, Moessler H, Doppler E, Hutter-Paier B, Windisch M. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. J Neural Transm (Vienna). 2006;113(7):855-868. Epub 2005 Dec 14. PMID: 16362636. https://doi.org/10.1007/s00702-005-0384-3
Riley C, Hutter-Paier B, Windisch M, et al. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J Neural Transm. 2006;113:103-110. https://doi.org/10.1007/s00702-005-0302-8
Chukanova EI. Sravnitel’nyj analiz effektivnosti tserebrolizina pri lechenii patsientov s khronicheskoj ishemiej mozga. Farmakoekonomicheskie aspekty. Trudnyj patsient. 2011;1. Accessed March 18, 2021. https://cyberleninka.ru/article/n/sravnitelnyy-analiz-effektivnosti-tserebrolizina-pri-lechenii-patsientov-s-hronicheskoy-ishemiey-mozga-farmakoekonomicheskie-aspekty
Putilina MV, Vechorko VI, Grishin DV, Sidelnicova LV. Acute cerebrovascular accidents associated with SARS-COV-2 coronavirus infection (COVID-19). S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120(12):109-117. (In Russ.). https://doi.org/10.17116/jnevro2020120121109
Alvarez XA, Sampedro C, Cacabelos R, Linares C, Aleixandre M, García-Fantini M, Moessler H. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin. Int J Neuropsychopharmacol. 2009;12(7):867-872. https://doi.org/10.1017/S1461145709990101
Putilina MV, Natarova EB. Features of manifestations of cerebral circulation insufficiency in young patients. Russian Medical News. 2002;1:41-44. (In Russ.).
Malashenkova IK, Krynskiy SA, Hailov NA, Ogurtsov DP, Selezneva ND, Fedorova YaB, Ponomareva EV, Kolyhalov IV, Gavrilova SI, Didkovsky NA. Anti-inflammatory effects of neurotrophic therapy (a pilot study). S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):39-44. (In Russ.). https://doi.org/10.17116/jnevro20181185139
Panteleeva GP, Artyukh VV, Krylova ES, Demeneva AA, Dikaya TI, Oleichik IV, Nikiforova IYu, Beburishvili AA. Optimization of psychopharmacotherapy of endogenous depression using the drug Cerebrolysin. Psychiatry and Psychopharmacotherapy. Journal named P.B. Gannushkin. 2012;14(1):24-30. (In Russ.).
Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Medicinal Research Reviews. 2020. https://doi.org/10.1002/med.21722
Gromova OA, Torshin IYu, Semenov VA, Putilina MV, Chuchalin AG. Direct and indirect neurological manifestations of COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(11):11-21. (In Russ.). https://doi.org/10.17116/jnevro202012011111
Putilina MV. Combined neuroprotective therapy for cerebrovascular diseases. Vrach. 2012;4:69-73. (In Russ.).